Pfizer (PFE) Other Non Operating Income (2009 - 2026)

Pfizer (PFE) has reported Other Non Operating Income for 18 consecutive years, with -$3.7 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Other Non Operating Income fell 402.84% year-over-year to -$3.7 billion in Q2 2026; TTM through Jun 2026 was -$9.6 billion, a 98.96% decrease from a year earlier, with the FY2025 full-year figure at -$6.7 billion, down 53.24% from the prior year.
• Other Non Operating Income was -$3.7 billion for Q2 2026 at Pfizer, down from -$861.0 million in the prior quarter.
• Over five years, Other Non Operating Income peaked at $159.0 million in Q4 2023 and troughed at -$4.5 billion in Q4 2025.
• A 5-year average of -$1.2 billion and a median of -$755.5 million in 2022 frame the typical range for Other Non Operating Income.
• Across the five-year window, Other Non Operating Income jumped 109.72% in 2023 and sank 1576.0% in 2024, its largest moves.
• Over 5 years, Other Non Operating Income stood at -$772.0 million in 2022, then surged by 120.6% to $159.0 million in 2023, then tumbled by 1376.73% to -$2.0 billion in 2024, then tumbled by 122.36% to -$4.5 billion in 2025, then gained by 17.68% to -$3.7 billion in 2026.
• The last three Other Non Operating Income figures came in at -$3.7 billion (Q2 2026), -$861.0 million (Q1 2026), and -$4.5 billion (Q4 2025), per Business Quant data.